Alaunos Therapeutics reported preclinical data showing its ALN1003 candidate demonstrated consistent improvements across multiple metabolic markers including body weight, insulin sensitivity, and liver health in diet-induced obese mice. The positive early-stage results support continued development of the non-hormonal, non-incretin obesity treatment candidate.